Edition:
United States

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

3.05USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
181,230
52-wk High
$10.05
52-wk Low
$2.72

Chart for

About

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant... (more)

Overall

Beta: 1.89
Market Cap(Mil.): $125.25
Shares Outstanding(Mil.): 41.07
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Advaxis Q4 loss per share $1.74

* Advaxis reports business update and third quarter 2017 results

Sep 11 2017

Advaxis CEO Daniel O'Connor resigns

Cancer immunotherapy developer Advaxis Inc said on Thursday Daniel O'Connor stepped down from his position as the company's chief executive and its board.

Jul 06 2017

Advaxis CEO Daniel O'Connor resigns

July 6 Cancer immunotherapy developer Advaxis Inc said on Thursday Daniel O'Connor stepped down from his position as the company's chief executive and its board.

Jul 06 2017

BRIEF-Advaxis names ‍Anthony Lombardo interim CEO

* Advaxis inc - ‍Anthony Lombardo named interim chief executive officer​

Jul 06 2017

Earnings vs. Estimates